Latest Macula of retina Stories
MIAMI LAKES, Fla., May 23, 2013 /PRNewswire/ -- Fuse Science, Inc. (OTCQB: DROP) (www.fusescience.com) a consumer products and delivery technology company that is developing new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals is pleased to announce, in partnership with Macular Health, LLC, advances in the development of an AREDS2 Drop formulation to combat Age-Related Macular Degeneration ("AMD"). AMD is a medical...
Ophthalmologist George Rozakis MD reviews why the recently completed AREDS2 study failed to provide incremental improvement in macular degeneration therapy and reviews a case history of a patient whose vision improved in weeks after using genetic testing to unblock methylation pathways, anti-oxidative therapy, hormonal restoration and genetically guided nutrition. Cleveland Ohio (PRWEB) May 16, 2013 George Rozakis MD, author and pioneering Ophthalmologist who helped innovate the Lasik...
ILUVIEN now available in Germany as a new treatment for chronic diabetic macular edema ATLANTA, May 7, 2013 /PRNewswire/-- Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that ILUVIEN(®), the first sustained release pharmaceutical product for the treatment of chronic diabetic macular edema (DME), is now commercially available...
CAMBRIDGE, Mass., May 7, 2013 /PRNewswire/ -- The Angiogenesis Foundation released a white paper that addresses the barriers faced by individuals in the Asia-Pacific region in seeking effective treatment for wet Age-Related Macular Degeneration (AMD), the second-leading cause of blindness in the world. The white paper, "Wet Age-Related Macular Degeneration in the Asia-Pacific: Critical Pathways Forward," is the result of the Asia-Pacific Wet Age-Related Macular Degeneration Expert...
CAMBRIDGE, Mass., May 5, 2013 /PRNewswire/ -- The Angiogenesis Foundation released a new white paper, "Advocating for Improved Treatment and Outcomes for Wet Age-Related Macular Degeneration" (AMD). Wet AMD is the most common form of blindness in people 50 years or older in developed nations. The report is based on the Australian Wet Age-Related Macular Degeneration Coalition Expert Summit convened in Sydney, Australia last July by the Angiogenesis Foundation and Macular Degeneration...
LEUVEN, Belgium, May 2, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA(R)in Germany, the second European market where the product is now available. Since May 1st, 2013, JETREA(R)is listed in the "Lauer-Taxe" (Grosse Deutsche Spezialitatentaxe) with an ex-factory price of EUR3,078....
Virginia Commonwealth University Implant improves vision for patients suffering from the leading cause of blindness in older Americans. The telescope implant is designed to correct end-stage age-related macular degeneration (AMD), the most advanced form of AMD and the leading cause of blindness in older Americans. Patients with end-stage AMD have a central blind spot. This vision loss makes it difficult or impossible to see faces, to read and to perform everyday activities such as...
AWARENESS SPEAKS TO GROWING INCREASE IN VISION PROBLEMS FOR WOMEN OF ALL AGES: SAN DIEGO, April 11, 2013 /PRNewswire/ -- Today, of the 3.4 million Americans suffering from visual impairment, about 2.3 million are women, and those that fall into the legally blind category, 70% of them are women. Much of the vision loss is the result of age-related conditions due to women living longer than men, making them more at risk for vision diseases like macular degeneration, which is a disease...
LEUVEN, Belgium, April 11, 2013 /PRNewswire/ -- First EU JETREA(R) order triggers EUR45 million milestone payment from Alcon to ThromboGenics ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines, today announces that its partner Alcon has launched JETREA(R) (ocriplasmin) in the UK, its first market in Europe....
[ Watch the Video: Cholesterol-Lowering Eye Drops Could Treat Macular Degeneration ] redOrbit Staff & Wire Reports - Your Universe Online Macular degeneration, the leading cause of blindness in Americans over the age of 50, could be treated using medications traditionally used to lower cholesterol levels, researchers from the Washington University School of Medicine in St. Louis claim in a new study. The investigators, who detailed their findings online in the journal Cell...
